National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits in the top decile of US sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count).
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): 490 sponsored US clinical trials, 50 recruiting.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsors 490 registered US clinical trials on ClinicalTrials.gov, 50 of them currently recruiting, and 398 completed. 69 of these trials are in Phase 3-4 (later-stage) and 178 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 25 trials.
Top-decile sponsor footprint
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ranks in the top decile of sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
398 of 424 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
490 total, page 6 of 10
Long-Term Exercise Maintenance Via Internet Support
NCT00260117
Metabolic Effects of Chemical Interactions in Toxicity
NCT00253773
Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)
NCT00063622
Weight Management in Nonalcoholic Steatohepatitis
NCT00266019
The Effect of Ethanol on Overnight Glucose Regulation in Type 2
NCT00566592
Donor Recipient Kidney Function Following Open Surgical vs. Laparoscopic Kidney Donation
NCT00100516
Effects of Hydrocortisone, Melatonin, and Placebo on Jet Lag
NCT00097474
PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C
NCT00100659
Podocyte Retinoids
NCT00098020
Adrenal Function in Critical Illness
NCT00156767
Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials
NCT00105352
Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)
NCT00135811
TEDDY - The Environmental Determinants of Diabetes in the Young
NCT00279318
Uric Acid in Essential Hypertension in Children
NCT00288184
Insulin Resistance in Severely Obese Patients
NCT00275223
Randomized Trial of EUS Neurolysis in Pancreas Cancer
NCT00279292
Infectious Agents in Pediatric Crohn's
NCT00237055
Program to Reduce Incontinence by Diet and Exercise
NCT00091988
Genetics of Interstitial Cystitis
NCT00237081
Reimbursement Effects on Enrollment in Obesity Treatment
NCT00250510
New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial
NCT00100178
Screening for Barrett's Esophagus in Otolaryngology Patients
NCT00695227
Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)
NCT00081328
Exercise Training in Type 2 Diabetes and Hypertension
NCT00212303
Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome
NCT00111956
Gender, Obesity, C-Reactive Protein, and Oxidative Stress
NCT00079963
The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients
NCT00080574
Minimally Invasive Surgical Therapy for BPH
NCT00064649
Events Preceding Interstitial Cystitis (EPIC)
NCT00248664
Metabolic Analysis in Human Sulfur Amino Acid Deficiency
NCT00253760
Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
NCT00076570
Obesity and Fatty Acid Flux Comparison Trials
NCT00074945
Kidney Transplantation in Patients With Cystinosis
NCT00074516
Improving Diabetes in Primary Care (IMPACT)
NCT00108927
The Effects of Overfeeding on Obesity-Prone (OP) and Obesity-Resistant (OR) Women
NCT00072917
Fat Cell Size in Insulin Resistance
NCT00341406
Enhanced Internet Behavior Therapy for Treating Obesity
NCT00212238
Videoendoscopic Drainage of Infected Pancreatic Collections
NCT00061269
Interaction of Cobalamin Status With Nitrous Oxide in Relation to Postoperative Cognitive Changes in the Elderly
NCT00212147
Islet Transplantation for Patients With Type 1 Diabetes
NCT00073281
Conservative Treatment of Postprostatectomy Incontinence
NCT00212264
Peer-enhanced Intervention to Support Teen Weight Loss
NCT00285558
The Effect of Vitamin D and Calcium on Bone in Pediatric HIV
NCT00724178
Improving Outcomes in Patients With Kidney Disease Due to Diabetes
NCT00381134
Evaluation of California's SB 19 Pupil Nutrition Act
NCT00067847
Steroid Treatment for Kidney Disease
NCT00065611
ORWH:SCOR on Sex and Gender Factors Affecting Women's Incontinence
NCT00069368
Evaluating the Use of Thymoglobulin, Sirolimus, and Donor Bone Marrow With Kidney Transplantation Patients
NCT00062712
Treating Nonalcoholic Steatohepatitis With Pioglitazone
NCT00062764
Treating Nonalcoholic Steatohepatitis (NASH) With Metformin
NCT00063232
What is open in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline
50 recruiting of 490 indexed (10% open); 398 completed (81%).
Phase mix: 69 late (III/IV) vs 178 early (I/II) (early-phase heavy).
Top condition: Obesity (25 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): open-pipeline peers nationwide
Peers matched on 490 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 490 trials (± recruiting share)
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
- Fred Hutchinson Cancer Center · 483 trials · 12% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Mirati Therapeutics · 10% recruiting · 49 trials
- James J. Peters Veterans Affairs Medical Center · 10% recruiting · 39 trials
- California Pacific Medical Center Research Institute · 10% recruiting · 29 trials
- National Institute of Environmental Health Sciences (NIEHS) · 10% recruiting · 145 trials
Related
What to do with this National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) page
490 registered trials is a research-attention snapshot, not an endorsement of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or any single study.
- 50 of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline card: 490 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.